Touchstone Innovations plc (AIM: IVO) made the investment.
A new spin-out company from Imperial College London, Cardian has been formed to commercialize a novel implantable device that improves the monitoring and treatment of cardiac failure patients, by providing automated, continuous wireless monitoring of blood pressure in the pulmonary artery.
The company has developed a fully implantable wireless pulmonary arterial pressure (PAP) sensor which needs neither batteries nor a power line. The sensor is read by an external body-worn portable reader the size of a smartphone, in real time, 24/7. This allows the continuous monitoring of the pulmonary arterial pressure during daily activity, including during periods of exertion and stress (rather than lying in a hospital bed).
Co-founded by Dr Christopher McLeod, Dr Mohammad Reza Bahmanyar, and Dr Longfang Zou of the Institute of Biomedical Engineering and the Department of Electrical and Electronic Engineering at Imperial College, the company is now led by newly appointed Chief Executive Officer Sandeep Yadav, who was previously COO of Cardiomems, one of the pioneers of the monitoring of pulmonary arterial pressure. Cardiomems was acquired by St Jude Medical for a total $450.0 million in 2014.